Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing
Market News Market Pulse Stocks News ETF News Crypto News

Connect Biopharma Holdings Limited

Contributing Author

Recent Articles by Connect Biopharma Holdings Limited

Sep-15
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation CNTB -32.17% GlobeNewswire
Sep-03
Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference CNTB -30.07% GlobeNewswire
Aug-12
Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update CNTB CNTB +9.01% GlobeNewswire
Jun-17
Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma CNTB GlobeNewswire
May-12
Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference CNTB +14.53% CNTB -8.58% GlobeNewswire
May-12
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update CNTB +14.53% GlobeNewswire
Apr-23
Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis CNTB GlobeNewswire
Mar-31
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update CNTB -9.66% GlobeNewswire
Mar-30
Connect Biopharma Announces $20.2 Million Private Placement Financing CNTB -15.94% GlobeNewswire
Mar-30
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study CNTB -15.94% GlobeNewswire
Mar-30
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD CNTB -15.94% GlobeNewswire
Mar-10
Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting CNTB +5.28% GlobeNewswire
Mar-03
Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference CNTB GlobeNewswire
Feb-19
Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference CNTB GlobeNewswire
Jan-12
Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026 CNTB GlobeNewswire
Nov-24
Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference CNTB GlobeNewswire
Nov-12
Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update CNTB +5.92% GlobeNewswire
Sep-29
Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025 CNTB -16.64% GlobeNewswire
Sep-04
Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025 CNTB -10.55% GlobeNewswire
Sep-03
Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq CNTB -5.69% GlobeNewswire
Aug-27
Connect Biopharma to Present at Two Upcoming Investor Conferences in September CNTB GlobeNewswire
Aug-14
Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide CNTB -8.90% GlobeNewswire
Aug-13
Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update CNTB GlobeNewswire
Jul-22
Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors CNTB +19.00% GlobeNewswire
Jul-21
Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq CNTB +16.28% GlobeNewswire
Jul-18
Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference CNTB -7.53% GlobeNewswire
Jul-17
Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement CNTB +14.81% GlobeNewswire
Jul-09
Connect Biopharma's Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China CNTB GlobeNewswire
Jun-13
Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress CNTB +11.76% GlobeNewswire
Jun-03
Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress CNTB GlobeNewswire
May-28
Connect Biopharma to Present at Two Upcoming Investor Conferences in June CNTB GlobeNewswire
May-20
Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference CNTB +8.12% GlobeNewswire
May-15
Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update CNTB -5.58% GlobeNewswire
May-14
Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD CNTB GlobeNewswire
May-13
Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma CNTB -5.16% GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)